Treatment of chronic osteoarthritis pain: Effectivity and safety of a 7 day matrix patch with a lowdose buprenorphine;Chronische arthroseschmerzen: Effektivität und verträglichkeit eines 7-tage-pflasters mit niedrig dosiertem buprenorphin: Ergebnisse einer multizentrischen anwendungsbeobachtung

MMW-Fortschritte der Medizin

Volumn 150, Issue 26-27 SUPPL., 2008, Pages 96-103

  Schutter, Ulf ^a   Ritzdorf, Ingrid ^b   Heckes, Birgit ^b  

^a Spezielle Schmerztherapie ^*  (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Buprenorphine; Matrix patch; Osteoarthritis; Pain

Indexed keywords

BUPRENORPHINE; CYCLOOXYGENASE 2 INHIBITOR; DIPYRONE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORSPAN; OPIATE DERIVATIVE; PARACETAMOL; TILIDINE; TRAMADOL;

CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MOBILIZATION; OSTEOARTHRITIS; PAIN ASSESSMENT; QUALITY OF LIFE; RATING SCALE; REVIEW; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, SUBLINGUAL; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PROSPECTIVE STUDIES;

EID: 47249098481     PISSN: 14383276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Arzneimittelkommission der deutschen Ärzteschaft. Empfehlungen zur Therapie von degenerativen Gelenkerkrankungen. AVP-Sonderheft Therapieempfehlungen, 2. Auflage, Köln 2001, 1-28.
2. Budd, K.: Buprenorphine and the transdermal system: the ideal match in pain management. Int. J. Clin. Pract. Suppl. 133 (2003), 9-14.
3. Dickson, D. J.: Opioids for non-operable osteoarthritis and soft-tissue rheumatism. Arthritis Res. Ther. 7 (2005), 193-194.
4. Griessinger, N., Sittl, R., Likar R.: Transdermal buprenorphine in clinical practice - a post-marketing surveillance study in 13.179 patients. Curr. Med. Res. Opin. 21 (2005), 1147-1156.
5. Likar, R.: Safety of pain management with transdermal buprenorphin. Ther. Clin. Risk Manag. 2 (2006), 115-125.
6. Minor, M. A.: Physical Therapy. In: Brandt, K. D., Doherty, M., Lohmander, L. S.: Osteoarthritis. Oxford University Press 2003, 299-310.
7. Norspan® bei chronischen Arthroseschmerzen. Wissenschaftliche Fachinformation. Grünenthal GmbH, Aachen 2007, 6-12.
8. Reidenberg, B., Eltahtawy, A., Munera, C., Cipriano, A., Tonelli, A., Reder, R.: Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days. J. Clin. Pharmacol. 41 (2001), 1027.
9. Robert Koch-Institut. Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes, Berlin 2006, 37-40.
10. Spyker, D. A., Hale, M., Munera, C. L., Wright, C.: Effectiveness and safety of buprenorphine transdermal system (BTDS) compared with hydrocodone/acetaminophen in the treatment of patients with chronic low back pain. Program and abstracts of the 21st Annuat Scientific Meeting of the American Pain Society; March 14-17, 2002; Baltimore, Maryland. J. Pain 3 (2002), 14 Abstract 653.
11. st Annual Scientific Meeting of the American Pain Society; March 14-17, 2002; Baltimore, Maryland. J. Pain 3 (1) (2002), 2 Abstract 645.
12. nd edition. Geneva, 1996, 1-70.